EQS-Adhoc: Polyphor announces financial results for the full-year 2018
15.03.2019 (www.4investors.de - in Kooperation mit DGAP - EQS Group):
EQS Group-Ad-hoc: Polyphor AG / Key word(s): Annual Results
Polyphor announces financial results for the full-year 2018
15-March-2019 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.
Allschwil, Switzerland, March 15, 2019
Polyphor announces financial results for the full-year 2018
- Successful listing on SIX Swiss Exchange raising CHF 155 million
- Murepavadin - Phase III PRISM-MDR trial started, Phase III PRISM-UDR trial enrolling first centers
- Balixafortide - Phase III study agreed with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and receives Fast Track designation
- OMPTA platform - lead compound identified and supported by Novo Holdings A/S and CARB-X
- Strong cash balance to finance pipeline to key inflection points
Polyphor AG (SIX: POLN), a clinical stage, Swiss biopharmaceutical company focused on the discovery and development of antibiotics and immuno-oncology compounds today announced its financial results for the full-year of 2018.
Successful listing on SIX Swiss Exchange
The listing of Polyphor on SIX Swiss Exchange on May 15, 2018 was the largest primary biotech IPO in Switzerland in over 10 years. With this transaction we were able to raise CHF 155 million which gives us the opportunity to advance the development of our pipeline, as well as to broaden our investor base, gaining the support of many new Swiss and international investors who see the value creation potential of our development programs and technology. Besides the IPO, we have made significant progress in the advancement of all of our key programs - murepavadin, balixafortide and the OMPTA platform.
In March 2018 the first patient was enrolled in the PRISM-MDR European Phase III clinical trial for the treatment of ventilator-associated bacterial pneumonia (VABP) due to Pseudomonas aeruginosa. The PRISM-MDR study will compare murepavadin combined with one other anti-pseudomonal antibiotic against two other anti-pseudomonal antibiotics, and is expected to take approximately two and a half years to complete. In 2019, the independent DSMB (Data Safety and Monitoring Board) made its first review and recommended the study to proceed without modifications. For the second pivotal Phase III study (PRISM-UDR) we have reached an agreement with the U.S. Food and Drug Administration (FDA) on the protocol for the study and have already started to enroll the first centers. The monotherapy study is designed to demonstrate non-inferiority of murepavadin compared to an anti-pseudomonal standard-of-care antibiotic in patients with hospital-acquired pneumonia due to Pseudomonas aeruginosa.
After the FDA granted Fast Track designation in the beginning of 2018 for our immuno-oncology candidate balixafortide, we could announce towards the end of the year positive results from the FDA Type B Guidance meeting on the planned Phase III study. The FDA reviewed the design and the inclusion and exclusion criteria of the international study, which will comprise a total of 384 patients and evaluate the efficacy and safety of balixafortide and eribulin versus eribulin monotherapy in patients with HER2-negative metastatic breast cancer. We are making further progress with the preparation of the planned single pivotal study, which started in the first quarter of 2019. In addition, we are conducting preclinical work to establish the potential of balixafortide in combination with other drugs and other oncology combinations and/or indications.
We progressed with the development of our OMPTA (Outer Membrane Protein Targeting Antibiotics) platform and identified the lead preclinical candidate, POL7306. We are honored that the Novo REPAIR Impact Fund has chosen our lead OMPTA compounds for their first investment. Novo Holdings A/S committed to invest up to CHF 11.5 million in Polyphor to accelerate the development of the novel OMPTA compound addressing the deadliest and most resistant Gram-negative bacterial pathogens including those designated as a critical concern by the World Health Organization (WHO). This represents a great endorsement of our efforts in finding new antibiotics to combat drug resistance. In addition, Polyphor was awarded a grant from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) of up to USD 5.6 million to fund the preclinical development and Phase I clinical trial of the recently selected novel OMPTA candidate POL7306. We are aiming to start the clinical studies with POL7306 in the first part of 2020. Finally, thanks to the work done on OMPTA, we are honored to have received the most important technology prize in Switzerland for innovation and technology transfer, from the Swiss Innovation Forum in the category "Innovation Leader".
Strong cash balance
In 2018 Polyphor was able to raise a total of CHF 162.8 million in gross proceeds, including CHF 155.0 from the IPO and CHF 6.8 million from the first tranche of the Novo REPAIR Impact Fund. This strong financial position allows us to maximize the potential of our lead candidates murepavadin and balixafortide, giving us the opportunity to continue the development of the pivotal trials and to pursue the development of our OMPTA program until the next inflection point.
With the initiation of the murepavadin Phase III trials and preparation of the pivotal trial of balixafortide, R&D costs increased by 37% compared to last year to a total of CHF 44.8 million. Overall revenues increased on a like-for like basis by CHF 6.3 million from the last reporting period to CHF 6.5 million, mainly associated with a licensing agreement with Santhera Pharmaceuticals Ltd. This brings our total cash position to CHF 133.8 million (cash and cash equivalents) as of December 31, 2018.
Priorities in 2019
For 2019 we will focus on advancing our pipeline, with special attention to the Phase III trials of our two lead candidates murepavadin and balixafortide. Our aim is to progress the enrollment of patients in the murepavadin PRISM-MDR study that was initiated last year, and start the dosing of the first patient in the PRISM-UDR study in the first half of 2019. We are also looking forward to starting the dosing of the first patient in the balixafortide Phase III study around mid-2019, which will be a significant step in bringing forward this new treatment option for metastatic breast cancer. With the commencement of the different clinical studies, we expect an increase in our research and development costs. In addition, we will continue to further develop our preclinical programs, such as our novel OMPTA candidate POL7306 against multidrug-resistant Gram-negative pathogens, and the inhaled formulation of murepavadin. In line with our strategy, we are also evaluating new partnerships for co-development or co-commercialization of balixafortide in particular regions and indications.
Full-year 2018 results conference call at 14.00 CET on March 15, 2018
Giacomo Di Nepi (CEO) and Kalina Scott (CFO) will provide a corporate and financial update, followed by a Q&A session.
(CH) +41 44 580 6522
(UK) +44 20 3009 2470
(USA) +1 87 7423 0830
To follow the presentation, please use the below webcast link (no audio signal):https://webcasts.eqs.com/polyphor20190315/no-audio
Please use the following link for the audio webcast with replay function (audio and slides):https://webcasts.eqs.com/polyphor20190315
Profit and Loss1
Research and development expenses
Average net cash burn3
Cash on hand
1) based on the consolidated IFRS financial statements2) 2017 figures have been restated to reflect the discontinued operations3) represents the average monthly cash used in operating and investing activities
The annual report 2018 is available for download on our website: https://www.polyphor.com/investor-relations/reporting/
For further information please contact:
Chief Financial Officer
Tel: +41 61 567 16 67
Dynamics Group AG
Tel: +41 43 268 32 31
Polyphor is a clinical stage, Swiss biopharmaceutical company focused on the discovery and development of antibiotics and immuno-oncology compounds. It has discovered and is developing the OMPTA (Outer Membrane Protein Targeting Antibiotics). The OMPTA are potentially the first new class of antibiotics against Gram-negative bacteria to have reached phase III stage in the last 50 years. The company's lead OMPTA, murepavadin, (POL7080) is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by WHO; in addition, Polyphor is developing a pipeline of further preclinical antibiotics based on its OMPTA platform. In addition, Polyphor is developing an immuno-oncology candidate, balixafortide (POL6326), which is starting a Phase III trial in combination with eribulin in patients with advanced breast cancer, and exploring in parallel its potential for further combinations and indications. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please visit www.polyphor.com.
This press release contains forward-looking statements which are based on current assumptions and forecasts of the Polyphor management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Polyphor's results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Polyphor disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Additional features:Document: http://n.eqs.com/c/fncls.ssp?u=DDAYKWBAEKDocument title: Polyphor_FY18 ResultsEnd of ad hoc announcement
+41 61 567 1600
+41 61 567 1601
SIX Swiss Exchange
End of Announcement
EQS Group News Service
787853 15-March-2019 CET/CEST
Weitere DGAP-News von20.08.2019 - DGAP-News: Deutsche Expertise steckt hinter der ersten LNG-Speicher- und Regasifizierungsanlage Westafrikas
20.08.2019 - Deutsche Expertise steckt hinter der ersten LNG-Speicher- und Regasifizierungsanlage Westafrikas
20.08.2019 - DGAP-News: Daimler Dieselskandal - Rückruf GLK 220, was Geschädigte jetzt tun sollten: Klage statt Update
20.08.2019 - Dieselskandal - Anwälte klagen gegen Bundesrepublik Deutschland auf Schadensersatz aus Staatshaftung und kündigen massenhaft Klagen an; Bundesminister Scheuer am Pranger
20.08.2019 - Für mehr WLAN-Hotspots in Gastronomie, Handel und Hotel: Führende Hotspot-Anbieter Socialwave und MeinHotspot schließen sich zusammen
4investors-News zu16.05.2019 - TUI Aktie: An dieser Aktienkurs-Marke scheint etwas zu passieren
15.05.2019 - ZEW-Lageindikator folgt der Produktion - Commerzbank Kolumne
15.02.2019 - Deutschland schrammt nur knapp an einer Rezession vorbei - Commerzbank Kolumne
07.02.2019 - Grenke steigert Gewinn - Dividende wird erhöht
07.02.2019 - Osram rauscht in die roten Zahlen - „zahlreiche Unwägbarkeiten”